We are the world's foremost drug discovery center focused solely on ALS. As a nonprofit biotech we operate without regard
to profit motive or politics. Led by people with ALS and drug development experts, we are funded by a global network of
supporters unified to end ALS.
Scroll to Learn More
The ALS Therapy Development Institute is our Cambridge, MA-based laboratory space, 100% dedicated to
innovative ALS research. It is funded by our global community.
Our innovative science and cutting edge approach have resulted in:
The ALS Therapy Development Institute and its scientists actively discover and develop treatments for ALS. We
are the world's first and largest nonprofit biotech focused 100 percent on ALS research. Led by people with ALS
and drug development experts, we understand the urgent need to slow and stop this disease.
Stephen Heywood was diagnosed with ALS at age 29. After finding no treatment options, his brother, James Allen
Heywood, realized that a gap existed in the preclinical development of therapeutics for ALS. In 1999, he
founded the ALS Therapy Development Institute in the basement of his family's Newton, MA home to bring
effective treatments to people living with ALS as quickly as possible. Although Stephen is no longer with us,
this same sense of hope and family drives every decision made at the Institute today.
PepsiCo and Albertsons Companies donated $100,000 to fund ALS research at the ALS Therapy Development Institute as part of the #ReasonstoCare campaign.
Schedule a tour
Meet the team
In my opinion, the research ALS TDI is doing will bring us closer to a cure than anything else going on.
We have met the people who work at ALS TDI and their passion shines through, their personal connections to this disease drive them. We believe they are one of the most progressive and effective insitutes around, and they will be part of the cure.
Jose supported ALS TDI because "of the Institute's single-minded focus on finding a solution for ALS, and doing so as a nonprofit biotech company with top-tier talent. Clear Objective + Solid Strategy + Stellar People = Desired Results."
José Cofiño (PALS, Died 2017)
Register now for our upcoming webinar on May 10th at 6pm: FDA approves Radicava - What do we need to know?
#WHATWOULDYOUGIVE to #ENDALS?
For ALS Awareness Month, join our #InThreeWords campaign on social media.
You can be a hero and give to ALS TDI to help us get more promising treatments out of our lab and into people living with ALS.
November 27 is
You've taken the challenge, now help
move promising treatments out of our
lab and into people living with ALS.
The 2018 Combined Federal Campaign has officially launched!
Help us continue to move more potential treatments into the clinic!
Stay up to date with ALS TDI by subscribing to our newsletter today!
Join the Ride to #EndALS